Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

BMC Medicine

Joerg J Meerpohl²  Bernd Wullich¹  Gerd Antes³  Bastian Keck¹  Frank Kunath³ 

[1] Department of Urology, University Clinic Erlangen, Krankenhausstr. 12, 91054 Erlangen, Germany;Pediatric Hematology and Oncology, Center for Pediatrics and Adolescent Medicine, University Medical;German Cochrane Center, Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, Berliner Allee 29, 79110 Freiburg/Br., Germany

关键词: Meta-analysis;    Systematic review;    Tamoxifen;    Gynecomastia;    Androgen suppression therapy;    Prostatic neoplasms;   

Others  :  857362
DOI  :  10.1186/1741-7015-10-96

 received in 2012-04-19, accepted in 2012-08-28,  发布年份 2012

【 摘 要 】

Background

Tamoxifen has emerged as a potential management option for gynecomastia and breast pain due to non-steroidal antiandrogens, and it is considered an alternative to surgery or radiotherapy. The objective of this systematic review was to assess the benefits and harms of tamoxifen, in comparison to other treatment options, for either the prophylaxis or treatment of breast events induced by non-steroidal antiandrogens in prostate cancer patients.

Methods

We searched CENTRAL, MEDLINE, EMBASE, reference lists, the abstracts of three major conferences and three trial registers to identify ongoing randomized controlled trials (RCTs). Two authors independently screened the articles identified, assessed the trial quality and extracted data. The protocol was prospectively registered (CRD42011001320; http://www.crd.york.ac.uk/PROSPERO webcite).

Results

Four studies were identified. Tamoxifen significantly reduced the risk of suffering from gynecomastia (risk ratio 9RR0 0.10, 95% CI 0.05 to 0.22) or breast pain (RR 0.06, 95% CI 0.02 to 0.17) at six months compared to untreated controls. Tamoxifen also showed a significant benefit for the prevention of gynecomastia (RR 0.22, 95% CI 0.08 to 0.58) and breast pain (RR 0.25, 95% CI 0.10 to 0.64) when compared to anastrozole after a median of 12 months. One study showed a significant benefit of tamoxifen for the prevention of gynecomastia (RR 0.24, 95% CI 0.09 to 0.65) and breast pain (RR 0.20, 95% CI 0.06 to 0.65) when compared with radiotherapy at six months. Radiotherapy increased the risk of suffering from nipple erythema and skin irritation, but there were no significant differences for any other adverse events (all P > 0.05).

Conclusions

The currently available evidence suggests good efficacy of tamoxifen for the prevention and treatment of breast events induced by non-steroidal antiandrogens. The impact of tamoxifen therapy on long-term adverse events, disease progression and survival remains unclear. Further large, well-designed RCTs, including long-term follow-ups, are warranted. Also, the optimal dose needs to be clarified.

【 授权许可】

   
2012 Kunath et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 168:9-12.
• [2]Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583.
• [3]Iversen P, Melezinek I, Schmidt A: Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001, 87:47-56.
• [4]Carswell CI, Figgitt DP: Bicalutamide: in early-stage prostate cancer. Drugs 2002, 62:2471-2479. discussion 2480-2471
• [5]McLeod DG, Iversen P: Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000, 56:713-720.
• [6]Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004, 172:1865-1870.
• [7]McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006, 97:247-254.
• [8]Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F: Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005, 23:808-815.
• [9]Perdona S, Autorino R, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR, Di Lorenzo G: Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005, 6:295-300.
• [10]Staiman VR, Lowe FC: Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology 1997, 50:929-933.
• [11]Parker LN, Gray DR, Lai MK, Levin ER: Treatment of gynecomastia with tamoxifen: A double-blind crossover study. Metabolism 1986, 35:705-708.
• [12]Fradet Y, Egerdie B, Andersen M, Tammela TLJ, Nachabe M, Armstrong J, Morris T, Navani S: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol 2007, 52:106-114.
• [13]Saltzstein D, Sieber P, Morris T, Gallo J: Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005, 8:75-83.
• [14]Di Lorenzo G, Autorino R: Bicalutamide-induced gynaecomastia: do we have the answer? Eur Urol 2007, 52:5-8.
• [15]Di Lorenzo G, Autorino R, Perdona S, De Placido S: Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol 2005, 6:972-979.
• [16]Autorino R, Perdona S, D'Armiento M, De Sio M, Damiano R, Cosentino L, Di Lorenzo G: Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis 2006, 9:109-114.
• [17]Boccardo F, Rubagotti A, Garofalo L, Di Tonno P, Conti G, Bertaccini A, De Antoni P, Galassi P, Siragusa A, Durand F: Tamoxifen (T) is more effective than anastrozole (A) in preventing gynecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts). 39th Annual Meeting of the American Society of Clinical Oncology, Chicago 2003. May 31-June 3, Abstract 1608
• [18]Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D: Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol 2005, 56:415-420.
• [19]Conti G, Cretarola E, Boccardo F, Battaglia M, Di Tonno P, Bertaccini A, De Antoni P, Zattoni F, Galassi P, Durand F: Tamoxifen is safe and effective in preventing gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer and does not alter treatment efficacy. 19th Congress of the European Association of Urology, Vienna 2004.
• [20]Fradet Y, Egerdie B, Andersen M, Tammela T, Nachabe M, Armstrong J, Morris T, Navani S: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer. 22nd Annual Congress of the European Association of Urology, Berlin 2007.
• [21]Di Lorenzo G, Perdona S, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R: Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005, 174:2197-2203.
• [22]Saltzstein D, Cantwell A, Sieber P, Ross JR, Silvay-Mandeau O, Gallo J: Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU Int 2002, 90(Suppl 2):119-122.
• [23]Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Galucci F, Aragona F, Di Tonno P, Boccardo F: An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen (T) schedules in preventing gynecomastia (gy) induced by bicalutamide monotherapy (BM) in prostate cancer patients (pca pts). J Clin Oncol 2009, 27:e16080.
• [24]Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Cortellini P, Martorana G, Lapini A, Boccardo F: An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010, 57:238-245.
• [25]Eaton AC, Makris A: Once weekly tamoxifen in the prevention of gynaecomastia and breast pain secondary to bicalutamide therapy. Congress of the American Urological Association, San Francisco 2004, a1069.
• [26]Ozen H, Akyol F, Toktas G, Eskicorapci S, Unluer E, Kuyumcuoglu U, Abay E, Cureklibatur I, Sengoz M, Yalcin V, Akpinar H, Zorlu F, Sengor F, Karaman I: Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? J Urol 2010, 184:519-524.
• [27]Van Poppel H: Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol 2007, 52:115.
• [28]Ryssel H, Germann G, Kollensperger E, Riedel K: Plastic surgery for the treatment of gynaecomastia following hormone therapy in prostate carcinoma. Urologe A 2008, 47:467-471.
• [29]Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K: Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004, 60:476-483.
• [30]Widmark A, Fossa SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O: Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003, 61:145-151.
• [31]Mermershtain W, Lazarev I, Regev E, Ariad S, Lavrenkov K: Prophylactic breast irradiation for prevention of gynecomastia caused by antiandrogen therapy with bicalutamide (casodex 150 mg/d) for prostatic cancer patients. 1st European Multidisciplinary Meeting on Urological Cancer, Barcelona 2007.
• [32]Fass D, Steinfeld A, Brown J, Tessler A: Radiotherapeutic prophylaxis of estrogen-induced gynecomastia: a study of late sequela. Int J Radiation Oncology Biol Phys 1986, 12:407-408.
• [33]Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L: Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 2005, 47:587-592.
• [34]Dicker AP: The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 2003, 4:30-36.
• [35]Nieder C, Pawinski A, Andratschke NH, Molls M: Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs? Radiat Oncol 2008, 3:2. BioMed Central Full Text
• [36]Rohrich RJ, Ha RY, Kenkel JM, Adams WP Jr: Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg 2003, 111:909-923. discussion 924-905
• [37]Boccardo F, Rubagotti A, Battaglia M, Zattoni F, Bertaccini A, Romagnoli A, Conti G: Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. Int J Biol Markers 2006, 21:123-126.
• [38]Serretta V, Allegro R, De Grande G, Nicolosi F, Iurato C, Mazza R, Oxenius I, Cosentino V, Vaccarella G, Falsaperla M, Melloni D, Karydi M: Management of bicalutamide induced gynaecomastia. A randomised study comparing therapy versus prophylaxis with tamoxifen. 23rd Annual Congress of the European Association of Urology, Milan 2008.
• [39]Serretta V, De Grande G, Lapira G, Nicolosi F, Iurato C, De Giacomo E, Ranno S, Cosentino V, Contino G, Falsaperla M, Melloni D, Antonia R, Allegro R: A randomized trial comparing tamoxifen therapy versus tamoxifen prophylaxis in bicalutamide induced gynecomastia. J Urol 2008, 179(4 Supplement):181.